Actively Recruiting
Study of PF-08634404 with Chemotherapy Compared to Nivolumab plus Chemotherapy for Advanced Gastric and Esophageal Adenocarcinoma
Led by Pfizer · Updated on 2026-10-13
840
Participants Needed
102
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a new medicine called PF-08634404 combined with chemotherapy in people with advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma who have not received prior treatment for their advanced disease. This Phase 23 trial aims to evaluate the safety and effectiveness of PF-08634404 with chemotherapy compared to an approved treatment nivolumab plus chemotherapy for this type of cancer. Participants receive PF-08634404 or nivolumab intravenously along with chemotherapy in repeated treatment cycles. The study has two parts the first part focuses on assessing safety and response to the study medicine combined with chemotherapy, while the second part compares the study medicine plus chemotherapy to nivolumab plus chemotherapy to see which treatment works better. During the trial, participants undergo medical tests to monitor safety, treatment response, and cancer progression using established criteria. Researchers measure outcomes such as objective response rate, progression-free survival, overall survival, and quality of life over approximately four years. Adverse events, laboratory results, and drug concentrations are also tracked throughout treatment and for 90 days after the last intervention.
CONDITIONS
Brief Title
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here